tiprankstipranks
Trending News
More News >
Extendicare (TSE:EXE)
TSX:EXE

Extendicare (EXE) AI Stock Analysis

Compare
219 Followers

Top Page

TSE:EXE

Extendicare

(TSX:EXE)

Select Model
Select Model
Select Model
Outperform 71 (OpenAI - 4o)
Rating:71Outperform
Price Target:
C$24.50
▲(10.26% Upside)
Extendicare's overall stock score is driven by strong earnings performance and positive technical indicators. The company's robust revenue growth and strategic acquisitions are significant strengths. However, high leverage and challenges in the Managed Services segment pose risks. The valuation is fair, and the dividend yield adds moderate income potential.
Positive Factors
Revenue Growth
Strong revenue growth driven by organic expansion and strategic acquisitions indicates a robust market position and potential for sustained growth.
Cash Generation
Strong cash generation supports financial stability, enabling investment in growth opportunities and providing a buffer against economic downturns.
Strategic Acquisitions
Strategic acquisitions enhance service offerings and market reach, strengthening competitive advantage and supporting long-term growth.
Negative Factors
High Leverage
High leverage can increase financial risk, limit flexibility, and strain cash flow, potentially impacting long-term financial health.
Managed Services Segment Decline
Decline in Managed Services revenue suggests challenges in maintaining service contracts, which could affect overall profitability and market position.
Construction Delays
Construction delays can postpone revenue generation from new facilities, impacting growth plans and potentially increasing costs.

Extendicare (EXE) vs. iShares MSCI Canada ETF (EWC)

Extendicare Business Overview & Revenue Model

Company DescriptionExtendicare Inc. is a leading provider of senior healthcare services in Canada, specializing in long-term care, home health care, and rehabilitation services. With a commitment to enhancing the quality of life for seniors, Extendicare operates a network of facilities that offer a range of personalized care options, including nursing care, assisted living, and specialized support for individuals with cognitive impairments. The company focuses on delivering compassionate and comprehensive care, ensuring that seniors receive the support they need to live fulfilling lives.
How the Company Makes MoneyExtendicare generates revenue primarily through government funding and private pay for its healthcare services. The majority of its income comes from long-term care facilities, where it receives per diem funding from provincial governments based on the level of care required by residents. Additionally, the company earns revenue from home health care services, which are often funded through a combination of public health insurance and private payments. Extendicare also has partnerships with various healthcare organizations and agencies, which help to expand its service offerings and enhance its market reach. These partnerships can lead to additional contracts and revenue opportunities. Furthermore, the company may benefit from economies of scale and operational efficiencies, which can improve profit margins across its service lines.

Extendicare Earnings Call Summary

Earnings Call Date:Nov 11, 2025
(Q3-2025)
|
% Change Since: |
Next Earnings Date:Feb 26, 2026
Earnings Call Sentiment Positive
Extendicare reported a strong third quarter with significant organic growth and successful acquisitions in the Home health care segment. Financial metrics such as EBITDA and margins showed positive trends. However, there were challenges in the Managed Services segment and some delays in construction projects.
Q3-2025 Updates
Positive Updates
Strong Organic Growth and Acquisitions
Q3 saw strong organic growth, with Home health care volumes at ParaMed increasing by 13% year-over-year. The acquisition of Closing the Gap contributed $24 million in revenue and $3.1 million in NOI, exceeding expectations.
Financial Performance and Margin Improvements
Adjusted EBITDA increased by 40.6% to $50.8 million, with Home health care leading the way. Home health care NOI margin improved by 230 basis points to 13.6%. AFFO increased to $0.31 per share, up 19.3% year-over-year.
Expansion in Long-Term Care Segment
Six homes under construction will add 1,408 new beds, replacing 1,097 Class C beds. A new 320-bed home in Sudbury is planned to start construction by the end of the year.
Liquidity and Credit Facility
Extended senior secured credit facility by $100 million, maintaining favorable liquidity with cash on hand of $166 million and access to a further $154 million under a revolving credit facility.
Negative Updates
Managed Services Segment Decline
Managed Services revenue decreased by $3.3 million to $15.6 million, and NOI declined by $1 million due to the loss of a management contract after the sale of 30 Long-Term Care homes.
Delayed Construction Completion
The Theodore Place location completion was delayed by a quarter, primarily due to tying in power with Hydro One.
Company Guidance
During Extendicare Inc.'s Third Quarter 2025 Analyst Conference Call, the company reported strong financial performance and strategic growth. Driven by a 13% year-over-year organic growth in Home health care volumes and the full impact of the Closing the Gap acquisition, the company's consolidated Q3 revenue increased by 22.6% to $440.3 million. The acquisition contributed $24 million in revenue and $3.1 million in NOI, while adjusted EBITDA rose to $50.8 million, a 40.6% increase from the prior year. Home health care NOI margin improved by 230 basis points to 13.6%. The company also expanded its senior secured credit facility by $100 million to support acquisitions, maintaining liquidity with $166 million in cash and access to a $154 million revolving credit facility. Additionally, Extendicare's AFFO increased to $0.31 per share, up 19.3% year-over-year, reducing the payout ratio to 45% on a trailing 12-month basis. The company's ongoing redevelopment agenda includes six homes under construction, aiming to introduce 1,408 new beds, with a $565 million development cost funded through a joint venture with Axium. The company remains committed to expanding Long-Term Care capacity and enhancing its Home health care services through strategic acquisitions and capital-efficient growth.

Extendicare Financial Statement Overview

Summary
Extendicare demonstrates solid financial performance with consistent revenue growth and strong operational margins. The company effectively generates returns on equity, but the high leverage poses potential risks. Cash flow metrics are positive, reflecting good cash management. Overall, Extendicare is in a stable financial position with opportunities to enhance profitability and reduce leverage.
Income Statement
75
Positive
Extendicare has shown consistent revenue growth, with a TTM revenue growth rate of 2.37%. The company maintains a strong gross profit margin of 77.05% in the TTM period, indicating efficient cost management. However, the net profit margin is relatively low at 5.23%, suggesting room for improvement in profitability. The EBIT and EBITDA margins are stable, reflecting solid operational performance.
Balance Sheet
60
Neutral
The balance sheet shows a high debt-to-equity ratio of 2.29 in the TTM period, indicating significant leverage, which could pose financial risks. However, the return on equity is strong at 65.66%, demonstrating effective use of equity to generate profits. The equity ratio is relatively low, suggesting a reliance on debt financing.
Cash Flow
70
Positive
Extendicare's cash flow performance is robust, with a positive free cash flow growth rate of 5.79% in the TTM period. The operating cash flow to net income ratio is 0.44, indicating that operating cash flows are adequately covering net income. The free cash flow to net income ratio of 0.61 suggests efficient cash conversion from profits.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue1.59B1.47B1.30B1.22B1.17B1.10B
Gross Profit859.13M168.00M167.62M76.83M115.61M201.16M
EBITDA177.36M155.27M98.63M48.90M67.46M125.79M
Net Income91.00M75.21M33.98M69.55M11.50M54.19M
Balance Sheet
Total Assets873.86M719.79M672.73M781.58M900.32M963.13M
Cash, Cash Equivalents and Short-Term Investments166.83M121.85M75.91M167.28M104.63M179.96M
Total Debt337.46M292.49M334.52M383.97M536.85M564.60M
Total Liabilities709.96M595.44M584.81M680.88M798.40M834.94M
Stockholders Equity163.90M124.35M87.92M100.70M101.92M128.19M
Cash Flow
Free Cash Flow99.69M101.69M-106.13M-2.76M-6.10M88.17M
Operating Cash Flow152.78M143.64M23.28M98.87M59.08M121.27M
Investing Cash Flow-105.92M-9.11M-84.45M155.64M-59.39M2.00M
Financing Cash Flow-35.44M-87.87M-30.93M-191.86M-74.84M-38.16M

Extendicare Technical Analysis

Technical Analysis Sentiment
Positive
Last Price22.22
Price Trends
50DMA
18.89
Positive
100DMA
16.20
Positive
200DMA
14.76
Positive
Market Momentum
MACD
0.95
Positive
RSI
64.03
Neutral
STOCH
46.04
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EXE, the sentiment is Positive. The current price of 22.22 is above the 20-day moving average (MA) of 21.79, above the 50-day MA of 18.89, and above the 200-day MA of 14.76, indicating a bullish trend. The MACD of 0.95 indicates Positive momentum. The RSI at 64.03 is Neutral, neither overbought nor oversold. The STOCH value of 46.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EXE.

Extendicare Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
C$1.85B20.4965.57%2.24%11.59%41.99%
71
Outperform
C$278.38M2.1539.85%2.33%-40.05%558.77%
63
Neutral
C$1.98B46.877.07%4.44%11.47%6.45%
59
Neutral
C$244.79M3,900.000.11%1.04%0.19%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:EXE
Extendicare
22.22
12.22
122.20%
TSE:CRRX
CareRx
3.87
1.85
91.58%
TSE:SIA
Sienna Senior Living
21.09
6.24
42.02%
TSE:DR
Medical Facilities
15.48
0.14
0.89%

Extendicare Corporate Events

Private Placements and FinancingM&A TransactionsBusiness Operations and Strategy
Extendicare Completes $200 Million Private Placement to Fund Strategic Acquisition
Positive
Dec 3, 2025

Extendicare has completed a $200 million private placement of common shares, issuing 10,640,000 shares at $18.80 each. The proceeds, approximately $192 million after fees, will be used to partially fund the acquisition of CBI Home Health by its subsidiary, ParaMed Inc. This acquisition is part of Extendicare’s strategy to expand its home health care services, positioning the company for growth in the Canadian senior care market.

M&A TransactionsBusiness Operations and Strategy
Extendicare Expands Home Health Care Business with CBI Acquisition
Positive
Nov 19, 2025

Extendicare has announced the acquisition of CBI Home Health for $570 million, aiming to expand its home health care business and strengthen its national leadership position. This acquisition will diversify ParaMed’s geographic footprint, enhance its capabilities with innovative care models, and is expected to result in significant financial synergies and increased earnings per share, thereby delivering strong value for customers and shareholders.

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
Extendicare’s Q3 2025 Results Show Strong Growth and Strategic Acquisition Impact
Positive
Nov 11, 2025

Extendicare reported strong financial results for the third quarter of 2025, highlighted by a significant increase in adjusted EBITDA and revenue, driven by the acquisition of Closing the Gap and growth in the home health care segment. The acquisition of Closing the Gap, a provider of nursing and allied health services, enhances Extendicare’s home health services and is expected to generate cost synergies and additional revenue, positioning the company for further growth in the seniors care market.

Dividends
Extendicare Declares October 2025 Dividend
Positive
Oct 15, 2025

Extendicare Inc. announced a cash dividend of C$0.042 per common share for October 2025, payable on November 17, 2025, to shareholders of record as of October 31, 2025. This announcement reflects Extendicare’s ongoing commitment to providing shareholder value and maintaining its position as a key player in the senior care industry in Canada.

Financial Disclosures
Extendicare Schedules Q3 2025 Financial Results Announcement and Conference Call
Neutral
Oct 7, 2025

Extendicare Inc. has announced the release of its third-quarter financial results for 2025, scheduled for November 11, with a subsequent conference call on November 12. This announcement is significant as it provides stakeholders with insights into the company’s financial performance and strategic positioning in the senior care industry, potentially impacting investor decisions and market perceptions.

Dividends
Extendicare Declares September 2025 Dividend
Positive
Sep 15, 2025

Extendicare Inc. has announced a cash dividend of C$0.042 per common share for September 2025, payable on October 15, 2025, to shareholders on record as of September 30, 2025. This announcement reflects the company’s ongoing commitment to providing value to its shareholders and maintaining its position as a key player in the senior care industry in Canada.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Dec 18, 2025